Autocrine/paracrine erythropoietin regulates migration and invasion potential and the stemness of human breast cancer cells

References

• Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol Dial Transplant 1999; 14:Suppl 2 22 - 8; http://dx.doi.org/10.1093/ndt/14.suppl_2.22; PMID: 10334664
   PubMed Web of Science ®Google Scholar
• Eckardt KU, Kurtz A. Regulation of erythropoietin production. Eur J Clin Invest 2005; 35:Suppl 3 13 - 9; http://dx.doi.org/10.1111/j.1365-2362.2005.01525.x; PMID: 16281953
   PubMedGoogle Scholar
• Jelkmann W. Regulation of erythropoietin production. J Physiol 2011; 589:1251 - 8; http://dx.doi.org/10.1113/jphysiol.2010.195057; PMID: 21078592
   PubMed Web of Science ®Google Scholar
• Wang GL, Semenza GL. Molecular basis of hypoxia-induced erythropoietin expression. Curr Opin Hematol 1996; 3:156 - 62; http://dx.doi.org/10.1097/00062752-199603020-00009; PMID: 9372067
   PubMedGoogle Scholar
• Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004; 43:649 - 59; http://dx.doi.org/10.2169/internalmedicine.43.649; PMID: 15468961
   PubMed Web of Science ®Google Scholar
• Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252:5558 - 64; PMID: 18467
   PubMed Web of Science ®Google Scholar
• Browne JK, Cohen AM, Egrie JC, Lai PH, Lin FK, Strickland T, Watson E, Stebbing N. Erythropoietin: gene cloning, protein structure, and biological properties. Cold Spring Harb Symp Quant Biol 1986; 51:693 - 702; http://dx.doi.org/10.1101/SQB.1986.051.01.082; PMID: 3472747
   PubMedGoogle Scholar
• Noguchi CT, Wang L, Rogers HM, Teng R, Jia Y. Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med 2008; 10:e36; http://dx.doi.org/10.1017/S1462399408000860; PMID: 19040789
   PubMedGoogle Scholar
• Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008; 67:39 - 61; http://dx.doi.org/10.1016/j.critrevonc.2008.03.006; PMID: 18434185
   PubMed Web of Science ®Google Scholar
• Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res 2006; 12:332 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-05-1771; PMID: 16428469
   PubMed Web of Science ®Google Scholar
• Hardee ME, Rabbani ZN, Arcasoy MO, Kirkpatrick JP, Vujaskovic Z, Dewhirst MW, Blackwell KL. Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther 2006; 5:356 - 61; http://dx.doi.org/10.1158/1535-7163.MCT-05-0196; PMID: 16505109
   PubMed Web of Science ®Google Scholar
• Acs G, Chen M, Xu X, Acs P, Verma A, Koch CJ. Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett 2004; 214:243 - 51; http://dx.doi.org/10.1016/j.canlet.2004.04.027; PMID: 15363551
   PubMed Web of Science ®Google Scholar
• Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X. Functional erythropoietin autocrine loop in melanoma. Am J Pathol 2005; 166:823 - 30; http://dx.doi.org/10.1016/S0002-9440(10)62303-6; PMID: 15743794
   PubMed Web of Science ®Google Scholar
• Lopez TV, Lappin TR, Maxwell P, Shi Z, Lopez-Marure R, Aguilar C, Rocha-Zavaleta L. Autocrine/paracrine erythropoietin signalling promotes JAK/STAT-dependent proliferation of human cervical cancer cells. Int J Cancer 2011; 129:2566 - 76; http://dx.doi.org/10.1002/ijc.25935; PMID: 21442620
   PubMed Web of Science ®Google Scholar
• Jeong JY, Hoxhaj G, Socha AL, Sytkowski AJ, Feldman L. An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. Mol Cancer Res 2009; 7:1150 - 7; http://dx.doi.org/10.1158/1541-7786.MCR-08-0243; PMID: 19567780
   PubMed Web of Science ®Google Scholar
• Pelekanou V, Kampa M, Kafousi M, Dambaki K, Darivianaki K, Vrekoussis T, Sanidas E, Tsiftsis DD, Stathopoulos EN, Castanas E. Erythropoietin and its receptor in breast cancer: correlation with steroid receptors and outcome. Cancer Epidemiol Biomarkers Prev 2007; 16:2016 - 23; http://dx.doi.org/10.1158/1055-9965.EPI-06-1023; PMID: 17932349
   PubMed Web of Science ®Google Scholar
• Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362:1255 - 60; http://dx.doi.org/10.1016/S0140-6736(03)14567-9; PMID: 14575968
   PubMed Web of Science ®Google Scholar
• Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005; 97:489 - 98; http://dx.doi.org/10.1093/jnci/dji087; PMID: 15812074
   PubMed Web of Science ®Google Scholar
• Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, Wiebe N, Klarenbach S. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009; 180:E62 - 71; http://dx.doi.org/10.1503/cmaj.090470; PMID: 19407261
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373:1532 - 42; http://dx.doi.org/10.1016/S0140-6736(09)60502-X; PMID: 19410717
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19:2865 - 74; PMID: 11387359
   PubMed Web of Science ®Google Scholar
• Savonije JH, van Groeningen CJ, van Bochove A, Honkoop AH, van Felius CL, Wormhoudt LW, Giaccone G. Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial. Eur J Cancer 2005; 41:1560 - 9; http://dx.doi.org/10.1016/j.ejca.2005.03.024; PMID: 15953714
   PubMed Web of Science ®Google Scholar
• Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005; 23:2597 - 605; http://dx.doi.org/10.1200/JCO.2004.12.027; PMID: 15452188
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983 - 8; http://dx.doi.org/10.1073/pnas.0530291100; PMID: 12629218
   PubMed Web of Science ®Google Scholar
• de Beça FF, Caetano P, Gerhard R, Alvarenga CA, Gomes M, Paredes J, Schmitt F. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. J Clin Pathol 2013; 66:187 - 91; http://dx.doi.org/10.1136/jclinpath-2012-201169; PMID: 23112116
   PubMed Web of Science ®Google Scholar
• Sporn MB, Roberts AB. Autocrine, paracrine and endocrine mechanisms of growth control. Cancer Surv 1985; 4:627 - 32; PMID: 3939685
   PubMedGoogle Scholar
• Maxwell PH, Pugh CW, Ratcliffe PJ. Inducible operation of the erythropoietin 3′ enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. Proc Natl Acad Sci U S A 1993; 90:2423 - 7; http://dx.doi.org/10.1073/pnas.90.6.2423; PMID: 8460154
   PubMed Web of Science ®Google Scholar
• Knowles HJ, Harris AL. Hypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesis. Breast Cancer Res 2001; 3:318 - 22; http://dx.doi.org/10.1186/bcr314; PMID: 11597321
   PubMed Web of Science ®Google Scholar
• Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001; 3:323 - 7; http://dx.doi.org/10.1186/bcr315; PMID: 11597322
   PubMed Web of Science ®Google Scholar
• Goonewardene TI, Sowter HM, Harris AL. Hypoxia-induced pathways in breast cancer. Microsc Res Tech 2002; 59:41 - 8; http://dx.doi.org/10.1002/jemt.10175; PMID: 12242695
   PubMed Web of Science ®Google Scholar
• Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92:5510 - 4; http://dx.doi.org/10.1073/pnas.92.12.5510; PMID: 7539918
   PubMed Web of Science ®Google Scholar
• Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994; 269:23757 - 63; PMID: 8089148
   PubMed Web of Science ®Google Scholar
• Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000; 35:71 - 103; http://dx.doi.org/10.1080/10409230091169186; PMID: 10821478
   PubMed Web of Science ®Google Scholar
• Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med 2002; 41:79 - 83; http://dx.doi.org/10.2169/internalmedicine.41.79; PMID: 11868612
   PubMed Web of Science ®Google Scholar
• Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29:625 - 34; http://dx.doi.org/10.1038/onc.2009.441; PMID: 19946328
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394:485 - 90; http://dx.doi.org/10.1038/28867; PMID: 9697772
   PubMed Web of Science ®Google Scholar
• Peinado H, Cano A. A hypoxic twist in metastasis. Nat Cell Biol 2008; 10:253 - 4; http://dx.doi.org/10.1038/ncb0308-253; PMID: 18311179
   PubMed Web of Science ®Google Scholar
• Garber K. New drugs target hypoxia response in tumors. J Natl Cancer Inst 2005; 97:1112 - 4; http://dx.doi.org/10.1093/jnci/dji261; PMID: 16077066
   PubMed Web of Science ®Google Scholar
• Onnis B, Rapisarda A, Melillo G. Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med 2009; 13:9A 2780 - 6; http://dx.doi.org/10.1111/j.1582-4934.2009.00876.x; PMID: 19674190
   PubMed Web of Science ®Google Scholar
• Phillips TM, Kim K, Vlashi E, McBride WH, Pajonk F. Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia 2007; 9:1122 - 9; http://dx.doi.org/10.1593/neo.07694; PMID: 18084619
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Y, Malek SN, Zheng P, Liu Y. Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011; 8:399 - 411; http://dx.doi.org/10.1016/j.stem.2011.02.006; PMID: 21474104
   PubMed Web of Science ®Google Scholar
• Harrison H, Rogerson L, Gregson HJ, Brennan KR, Clarke RB, Landberg G. Contrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ER-α status. Cancer Res 2013; 73:1420 - 33; http://dx.doi.org/10.1158/0008-5472.CAN-12-2505; PMID: 23248117
   PubMed Web of Science ®Google Scholar
• Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000; 58:647 - 57; http://dx.doi.org/10.1046/j.1523-1755.2000.00211.x; PMID: 10916088
   PubMed Web of Science ®Google Scholar
• Arcasoy MO, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA, Haroon ZA. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002; 82:911 - 8; http://dx.doi.org/10.1097/01.LAB.0000020415.72863.40; PMID: 12118093
   PubMed Web of Science ®Google Scholar
• Lai SY, Grandis JR. Understanding the presence and function of erythropoietin receptors on cancer cells. J Clin Oncol 2006; 24:4675 - 6; http://dx.doi.org/10.1200/JCO.2006.08.1190; PMID: 17028292
   PubMed Web of Science ®Google Scholar
• LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 2006; 5:347 - 55; http://dx.doi.org/10.1158/1535-7163.MCT-05-0203; PMID: 16505108
   PubMed Web of Science ®Google Scholar
• Della Ragione F, Cucciolla V, Borriello A, Oliva A, Perrotta S. Erythropoietin receptors on cancer cells: a still open question. J Clin Oncol 2007; 25:1812 - 3, author reply 1815; http://dx.doi.org/10.1200/JCO.2006.09.7212; PMID: 17470877
   PubMed Web of Science ®Google Scholar
• Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 2010; 18:423 - 35; http://dx.doi.org/10.1016/j.ccr.2010.10.025; PMID: 21075308
   PubMed Web of Science ®Google Scholar
• Kumar A, Xu J, Sung B, Kumar S, Yu D, Aggarwal BB, Mehta K. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 2012; 14:R4; http://dx.doi.org/10.1186/bcr3085; PMID: 22225906
   PubMedGoogle Scholar
• Shaw FL, Harrison H, Spence K, Ablett MP, Simões BM, Farnie G, Clarke RB. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J Mammary Gland Biol Neoplasia 2012; 17:111 - 7; http://dx.doi.org/10.1007/s10911-012-9255-3; PMID: 22665270
   PubMed Web of Science ®Google Scholar